Journal of the American Pharmacists Association : JAPhA · 2023
Hepatitis B prophylaxis among recipients of a hepatitis B core antibody positive liver transplant.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tilley Madeleine S, Sparkman Taylor L, James Alexandra P, Li Peng, Gutierrez Kristofer C
Аннотация
OBJECTIVE: Using organs from donors with a history of hepatitis B virus (HBV) infection has expanded the pool for solid organ transplant. The purpose of this study was to assess the efficacy of HBV postexposure prophylaxis among recipients of a hepatitis B core antibody positive (HBcAb+) liver transplant and compare post-transplant outcomes with those who received a hepatitis B core antibody negative (HBcAb-) liver transplant.
METHODS: This was a retrospective, single-center cohort analysis of liver transplant recipients at our institution. All adult liver transplant recipients between January 1, 2014, and August 30, 2020, were reviewed for inclusion. Recipients of an HBcAb+ organ who were administered antiviral therapy were matched 1:2 with recipients of an HBcAb- organ using propensity score matching. The primary outcome was breakthrough HBV infection. Secondary outcomes included graft survival, patient survival, and allograft rejection. Postexposure prophylaxis strategies for HBV were also assessed. Outcomes were analyzed for the first 12 months after transplant.
RESULTS: Twenty-four HBcAb+ patients were matched to 48 HBcAb- patients. There were no documented cases of breakthrough HBV infection. Patient and graft survival was similar between both groups. Seven HBcAb+ patients (29%) experienced an episode of rejection within the first year compared with zero HBcAb- patients.
CONCLUSIONS: Results of this study suggest that current strategies for HBV postexposure prophylaxis are effective. Patient and graft survival rates at 30 days after transplant were similar to institutional reported values. Rejection was more prominent in the HBcAb+ group.
METHODS: This was a retrospective, single-center cohort analysis of liver transplant recipients at our institution. All adult liver transplant recipients between January 1, 2014, and August 30, 2020, were reviewed for inclusion. Recipients of an HBcAb+ organ who were administered antiviral therapy were matched 1:2 with recipients of an HBcAb- organ using propensity score matching. The primary outcome was breakthrough HBV infection. Secondary outcomes included graft survival, patient survival, and allograft rejection. Postexposure prophylaxis strategies for HBV were also assessed. Outcomes were analyzed for the first 12 months after transplant.
RESULTS: Twenty-four HBcAb+ patients were matched to 48 HBcAb- patients. There were no documented cases of breakthrough HBV infection. Patient and graft survival was similar between both groups. Seven HBcAb+ patients (29%) experienced an episode of rejection within the first year compared with zero HBcAb- patients.
CONCLUSIONS: Results of this study suggest that current strategies for HBV postexposure prophylaxis are effective. Patient and graft survival rates at 30 days after transplant were similar to institutional reported values. Rejection was more prominent in the HBcAb+ group.